Cantuzumab mertansine
MUC1 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Cantuzumab mertansine (SB-408075; huC242-DM1) is an
.Mechanism
After the huC242 mab binds to the external domain of
disulfide bonds.[3]
Clinical trials
Three phase I clinical studies had reported results by 2003.[4] By 2005, clinical development had been suspended.[5]
See also
References
- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Cantuzumab mertansine, American Medical Association. Archived 2011-06-04 at the Wayback Machine
- S2CID 5829870.
- PMID 15240523.
- PMID 15663331.
- ^ "Cantuzumab mertansine". Springer Nature Switzerland AG.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |